Insider Trading activities of Geron Corp insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Geron Corp since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Geron Corp since year 2005. Table 2 shows the detailed insider transactions of Geron Corp since 2005. The reporting company's ticker symbol is GERN. The reporting company's CIK number is 886744.
The total value of stock buying since 2005 is $503,126.
The total value of stock sales since 2005 is $4,985,682.
The total value of stock option exercises since 2005 is $566,322.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Geron Corp (GERN).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2015-05 0 $0 4,760 $18,278 0 $0
2015-03 0 $0 70,000 $287,000 70,000 $87,849
2014-05 142,776 $249,858 8,205 $17,229 0 $0
2014-04 0 $0 19,745 $42,056 0 $0
2013-04 50,000 $51,500 0 $0 0 $0
2013-01 0 $0 28,292 $46,568 0 $0
2012-05 0 $0 66,394 $90,958 0 $0
2011-11 64,275 $100,269 0 $0 0 $0
2011-10 50,000 $101,499 0 $0 0 $0
2011-06 0 $0 144,237 $617,332 0 $0
2011-05 0 $0 29,169 $135,482 0 $0
2010-06 0 $0 73,657 $399,954 0 $0
2010-05 0 $0 15,567 $79,543 0 $0
2010-04 0 $0 3,707 $20,981 0 $0
2009-05 0 $0 136,250 $911,268 0 $0
2009-04 0 $0 5,195 $23,065 0 $0
2009-02 0 $0 14,765 $119,891 0 $0
2009-01 0 $0 137,794 $906,890 48,617 $225,388
2008-11 0 $0 23,845 $96,572 0 $0
2008-01 0 $0 59,849 $319,590 0 $0
2007-11 0 $0 4,000 $28,800 0 $0
2007-05 0 $0 30,000 $275,310 35,000 $181,890
2006-04 0 $0 0 $0 29,411 $59,998
2006-03 0 $0 0 $0 5,489 $11,197
2006-01 0 $0 64,126 $548,915 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Geron Corp insiders (GERN)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2015-05-29 Bloom Olivia Kyusuk (EVP, Chief Financial Officer) Sale 2,380 3.84 9,139
2015-05-29 Behrs Melissa Kelly (EVP BD and Port&Alliance Mgmt) Sale 2,380 3.84 9,139
2015-03-18 Hofstaetter Thomas (Director) Sale 70,000 4.10 287,000
2015-03-18 Hofstaetter Thomas (Director) Option Ex 70,000 1.26 87,849
2014-05-29 Bloom Olivia Kyusuk (EVP, Chief Financial Officer) Sale 3,379 2.10 7,095
2014-05-29 Behrs Melissa Kelly (EVP Portfolio & Alliance Mgmt) Sale 4,826 2.10 10,134
2014-05-09 Bradbury Daniel (Director) Buy 142,776 1.75 249,858
2014-04-01 Bloom Olivia Kyusuk (EVP, Chief Financial Officer) Sale 7,435 2.13 15,836
2014-04-01 Behrs Melissa Kelly (EVP Portfolio & Alliance Mgmt) Sale 12,310 2.13 26,220
2013-04-01 Scarlett John A (President and CEO) Buy 50,000 1.03 51,500
2013-01-17 Behrs Melissa Kelly (SVP Alliance and Prog Mgmt) Sale 28,292 1.65 46,568
2012-05-30 Bloom Olivia Kyusuk (VP, Chief Acctg Officer) Sale 11,029 1.37 15,109
2012-05-30 Kelsey Stephen Michael (EVP, R&D Head, CMO) Sale 9,300 1.37 12,741
2012-05-30 Behrs Melissa Kelly (SVP Strategic Portfolio Mgmt) Sale 18,910 1.37 25,906
2012-05-30 Earp David (SVP, Corp Transactions) Sale 27,155 1.37 37,202
2011-11-22 Kiley Thomas (Director) Buy 64,275 1.56 100,269
2011-10-05 Kiley Thomas (Director) Buy 50,000 2.03 101,499
2011-06-14 Bloom Olivia Kyusuk (VP, Chief Acctg Officer) Sale 6,997 4.28 29,947
2011-06-14 Kelsey Stephen Michael (EVP, R&D Head, CMO) Sale 4,858 4.28 20,792
2011-06-14 Spink Katharine E. (SVP Alliance Mgmt & Operations) Sale 22,591 4.28 96,689
2011-06-14 Lebkowski Jane (SVP, Chief Scientific Officer) Sale 25,262 4.28 108,121
2011-06-14 Behrs Melissa Kelly (SVP Strategic Portfolio Mgmt) Sale 25,262 4.28 108,121
2011-06-14 Greenwood David (President, Interim CEO, CFO) Sale 34,005 4.28 145,541
2011-06-14 Earp David (Chief Legal Counsel) Sale 25,262 4.28 108,121
2011-05-24 Bloom Olivia Kyusuk (VP, Chief Acctg Officer) Sale 1,200 4.47 5,364
2011-05-24 Spink Katharine E. (SVP Prgm Mgmt, Cell Therapies) Sale 419 4.47 1,872
2011-05-24 Lebkowski Jane (SVP, Chief Scientific Officer) Sale 2,975 4.47 13,298
2011-05-24 Behrs Melissa Kelly (SVP Strategic Portfolio Mgmt) Sale 2,975 4.47 13,298
2011-05-24 Greenwood David (President, Interim CEO, CFO) Sale 4,462 4.47 19,945
2011-05-24 Earp David (SVP Bus Dev, Chief Patnt Couns) Sale 2,975 4.47 13,298
2011-05-05 Kelsey Stephen Michael (EVP, CMO, Oncology) Sale 14,163 4.83 68,407
2010-06-02 Spink Katharine E. (VP Operations, Regen Med Progs) Sale 8,186 5.43 44,449
2010-06-02 Okarma Thomas (President and CEO) Sale 18,874 5.43 102,485
2010-06-02 Lebkowski Jane (SVP, CSO Regen Med) Sale 10,617 5.43 57,650
2010-06-02 Behrs Melissa Kelly (SVP Oncology) Sale 10,617 5.43 57,650
2010-06-02 Greenwood David (EVP and CFO) Sale 14,746 5.43 80,070
2010-06-02 Earp David (SVP Bus Dev, Chief Patnt Couns) Sale 10,617 5.43 57,650
2010-05-24 Spink Katharine E. (VP Operations, Regen Med Progs) Sale 385 5.11 1,967
2010-05-24 Okarma Thomas (President and CEO) Sale 4,671 5.11 23,868
2010-05-24 Lebkowski Jane (SVP, CSO Regen Med) Sale 2,336 5.11 11,936
2010-05-24 Behrs Melissa Kelly (SVP Oncology) Sale 2,336 5.11 11,936
2010-05-24 Greenwood David (EVP and CFO) Sale 3,503 5.11 17,900
2010-05-24 Earp David (SVP Bus Dev, Chief Patnt Couns) Sale 2,336 5.11 11,936
2010-04-28 Kelsey Stephen Michael (EVP, CMO, Oncology) Sale 3,707 5.66 20,981
2009-05-29 Spink Katharine E. (VP Operations, Regen Med Progs) Sale 400 6.35 2,540
2009-05-29 Benedetti Fabio M (SVP, Chief Med Off, Oncology) Sale 2,277 6.35 14,458
2009-05-29 Okarma Thomas (President and CEO) Sale 5,828 6.35 37,007
2009-05-29 Lebkowski Jane (SVP, CSO Regen Med) Sale 2,277 6.35 14,458
2009-05-29 Behrs Melissa Kelly (SVP Oncology) Sale 2,277 6.35 14,458
2009-05-29 Harley Calvin (VP, CSO Telomerase Tech) Sale 2,277 6.35 14,458
2009-05-29 Greenwood David (EVP and CFO) Sale 3,416 6.35 21,691
2009-05-29 Earp David (SVP Bus Dev, Chief Patnt Couns) Sale 2,277 6.35 14,458
2009-05-26 Spink Katharine E. (VP Operations, Regen Med Progs) Sale 2,864 6.75 19,332
2009-05-26 Okarma Thomas (President and CEO) Sale 46,669 6.75 315,015
2009-05-26 Lebkowski Jane (SVP, CSO Regen Med) Sale 14,092 6.75 95,121
2009-05-26 Behrs Melissa Kelly (SVP Oncology) Sale 6,819 6.75 46,028
2009-05-26 Harley Calvin (VP, CSO Telomerase Tech) Sale 10,001 6.75 67,506
2009-05-26 Greenwood David (EVP and CFO) Sale 19,320 6.75 130,410
2009-05-26 Earp David (SVP Bus Dev, Chief Patnt Couns) Sale 15,456 6.75 104,328
2009-04-03 Benedetti Fabio M (SVP, Chief Med Off, Oncology) Sale 5,195 4.44 23,065
2009-02-02 Behrs Melissa Kelly (SVP Oncology) Sale 14,765 8.12 119,891
2009-01-30 Walker John Peter (Director) Sale 48,617 8.28 402,548
2009-01-30 Walker John Peter (Director) Option Ex 48,617 4.64 225,388
2009-01-29 Harley Calvin (VP and CSO) Sale 30,489 7.11 216,776
2009-01-05 Okarma Thomas (President and CEO) Sale 12,512 4.90 61,308
2009-01-05 Lebkowski Jane (SVP Regen Medicine) Sale 8,861 4.90 43,418
2009-01-05 Behrs Melissa Kelly (SVP Oncology) Sale 8,861 4.90 43,418
2009-01-05 Harley Calvin (VP and CSO) Sale 8,861 4.90 43,418
2009-01-05 Greenwood David (EVP and CFO) Sale 10,732 4.90 52,586
2009-01-05 Earp David (SVP Bus Dev, Chief Patnt Couns) Sale 8,861 4.90 43,418
2008-11-05 Behrs Melissa Kelly (SVP Oncology) Sale 23,845 4.05 96,572
2008-01-04 Okarma Thomas (President and CEO) Sale 13,166 5.34 70,306
2008-01-04 Lebkowski Jane (SVP Regen Medicine) Sale 8,911 5.34 47,584
2008-01-04 Behrs Melissa Kelly (SVP Oncology) Sale 8,911 5.34 47,584
2008-01-04 Harley Calvin (VP and CSO) Sale 8,911 5.34 47,584
2008-01-04 Greenwood David (EVP and CFO) Sale 11,039 5.34 58,948
2008-01-04 Earp David (SVP Bus Dev, Chief Patnt Couns) Sale 8,911 5.34 47,584
2007-11-12 Greenwood David (EVP and CFO) Sale 4,000 7.20 28,800
2007-05-21 Barkas Alexander E (Director) Option Ex 5,000 9.00 45,000
2007-05-18 Harley Calvin (VP and CSO) Sale 30,000 9.18 275,310
2007-05-18 Harley Calvin (VP and CSO) Option Ex 30,000 4.56 136,890
2006-04-28 Barkas Alexander E (Director) Option Ex 29,411 2.04 59,998
2006-03-08 Harley Calvin (Chief Scientific Officer) Option Ex 5,489 2.04 11,197
2006-01-09 Okarma Thomas (President and CEO) Sale 12,320 8.56 105,459
2006-01-09 Lebkowski Jane (SVP, Regenerative Me) Sale 10,676 8.56 91,386
2006-01-09 Behrs Melissa Kelly (VP, Oncology) Sale 8,441 8.56 72,254
2006-01-09 Harley Calvin (Chief Scientific Officer) Sale 9,183 8.56 78,606
2006-01-09 Greenwood David (Executive VP and CFO) Sale 12,183 8.56 104,286
2006-01-09 Earp David (SVP Bus Dev / Chf Pa) Sale 11,323 8.56 96,924

Insider trading activities including stock purchases, stock sales, and option exercises of GERN listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Geron Corp (symbol GERN, CIK number 886744) see the Securities and Exchange Commission (SEC) website.